Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sanofi Begins Japan PII for Type 1 Diabetes Med Teplizumab
August 22, 2025
- Meiji Group Launches PII Trial of Dengue Vaccine in Thailand
August 22, 2025
- Itochu Launches J-STEP to Help Overseas Drug Makers Tackle Japan’s “Drug Loss”
August 21, 2025
- ASKA, MICIN Team Up to Develop IBS Treatment App
August 21, 2025
- AnGes Taps Boehringer for Collategene Manufacturing
August 21, 2025
- Rohto Pairs Up with Exorphia in Regenerative Medicine
August 21, 2025
- FRONTEO, Daiichi Sankyo Expand AI Collaboration into Toxicity Data Analysis
August 20, 2025
- PPIs Prescribed to 6.38 Million in July, Two APIs Control 60%: Intage
August 20, 2025
- FDA Pushes Back Decision on Hunter Syndrome Gene Therapy
August 20, 2025
- Santen Secures Asia Rights to RemeGen’s VEGF/FGF Eye Drug RC28-E
August 20, 2025
- Foreign Pharma Sales in Japan Projected to Rise 1.8% in 2025: Fuji Keizai
August 20, 2025
- Alloy Japan Looks to Turn iCAR-T into Shared Infrastructure, IND Filing Slated for 2026
August 20, 2025
- Marubeni Expands Pharma Sales Biz into Africa with Phillips Investment
August 20, 2025
- Daiichi Sankyo Snares First FDA Breakthrough Tag for ADC I-DXd
August 20, 2025
- Keytruda Retains Top Spot in Japan Drug Market in April-June: IQVIA
August 20, 2025
- Mounjaro Wins Double Crown in June GP Promotion: Intage
August 20, 2025
- Dalton Signals Plan to Lift ASKA Stake to 30%; Board Weighs Countermeasures
August 19, 2025
- MSD Rolls Out Airwin and Welireg in Japan
August 19, 2025
- AGs Identified for 4 Brands in Latest Generic Approvals, Including Bonviva and Epadel
August 19, 2025
- Mochida’s Low-Dose Lialda to Hit Shelves in September
August 19, 2025
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…